Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)
National Institutes of Health
Award ceiling
—Award floor
—Posted
Aug 31, 2026Closes
Jan 11, 2027Location eligibility
No specific state restriction found in this listing — check the full opportunity for details.Categories: Health
Eligible applicants: Private institutions of higher education, Others (see text field entitled "Additional Information on Eligibility" for clarification), Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, City or township governments, State governments, Native American tribal organizations (other than Federally recognized tribal governments), County governments, Native American tribal governments (Federally recognized), Special district governments, Public and State controlled institutions of higher education, Independent school districts, For profit organizations other than small businesses, Public housing authorities/Indian housing authorities, Small businesses, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms.To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams will be established, each team capable of driving therapeutic agent(s) from pre-clinical development, through investigational new drugs (IND) studies, into pilot clinical studies in humans. Appropriate therapeutic agents include: (1) novel agents or (2) agents or combinations approved for other indications and repurposed for treatment of GBM following appropriate preclinical studies. The scope of the NOFO, from late pre-clinical through early (Phase 0/1) clinical studies, uniquely spans a gap in the GBM drug development process.